Efocipegtrutide Explained

Drug Name:	Efocipegtrutide
Synonyms:	HM15211
Legal Status:	Investigational
Cas Number:	2513399-19-2
Unii:	TUI1MDD9F6
Chembl:	5095149

Efocipegtrutide (HM15211) is a triple agonist of the glucagon, GIP, and glucagon-like peptide 1 receptors. It is being studied for obesity and nonalcoholic steatohepatitis.^{[1] [2] [3]}

Notes and References

1. Kalra . Sanjay . Bhattacharya . Saptarshi . Kapoor . Nitin . Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs) . Diabetes Therapy . August 2021 . 12 . 8 . 2133–2147 . 10.1007/s13300-021-01113-y . 34268675 . 8342688 . 1869-6953.
2. Kim . Jung Kuk . Lee . Jong Suk . Park . Eunjin . Lee . Jongsoo . Bae . Sungmin . Kim . Daejin . Choi . In Young . 1804-P: HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN/TAA–Induced Liver Inflammation and Fibrosis Mice . Diabetes . 1 June 2020 . 69 . Supplement_1 . 10.2337/db20-1804-P. 225811407 .
3. Abdelmalek . Manal F. . Suzuki . Ayako . Sanchez . Willian . Lawitz . Eric . Filozof . Claudia . Cho . Hyungjin . Baek . Eunhye . Choi . JaeDuk . Baek . Seungjae . A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study . Contemporary Clinical Trials . July 2023 . 130 . 107176 . 10.1016/j.cct.2023.107176 . 37028504 . 258001100 . 1559-2030.